Trial · NCT01238861
Adverse events438
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 438
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Injection site erythema | General disorders | EOS POS Placebo | 0 | 80 | 0 |
| other | Injection site erythema | General disorders | EOS POS Benralizumab 2 mg | 2 | 81 | 2 |
| other | Injection site erythema | General disorders | EOS POS Benralizumab 20 mg | 2 | 81 | 4 |
| other | Injection site erythema | General disorders | EOS POS Benralizumab 100 mg | 8 | 82 | 17 |
| other | Injection site erythema | General disorders | EOS NEG Placebo | 0 | 141 | 0 |
| other | Injection site erythema | General disorders | EOS NEG Benralizumab 100 mg | 10 | 141 | 17 |
| other | Influenza | Infections and infestations | EOS POS Placebo | 4 | 80 | 4 |
| other | Influenza | Infections and infestations | EOS POS Benralizumab 2 mg | 3 | 81 | 5 |
| other | Influenza | Infections and infestations | EOS POS Benralizumab 20 mg | 7 | 81 | 7 |
| other | Influenza | Infections and infestations | EOS POS Benralizumab 100 mg | 6 | 82 | 6 |
| other | Influenza | Infections and infestations | EOS NEG Placebo | 10 | 141 | 11 |
| other | Influenza | Infections and infestations | EOS NEG Benralizumab 100 mg | 6 | 141 | 6 |
| other | Sinusitis | Infections and infestations | EOS POS Placebo | 3 | 80 | 6 |
| other | Sinusitis | Infections and infestations | EOS POS Benralizumab 2 mg | 4 | 81 | 7 |
| other | Sinusitis | Infections and infestations | EOS POS Benralizumab 20 mg | 3 | 81 | 3 |
| other | Sinusitis | Infections and infestations | EOS POS Benralizumab 100 mg | 2 | 82 | 3 |
| other | Sinusitis | Infections and infestations | EOS NEG Placebo | 2 | 141 | 2 |
| other | Sinusitis | Infections and infestations | EOS NEG Benralizumab 100 mg | 0 | 141 | 0 |
| other | Nausea | Gastrointestinal disorders | EOS POS Placebo | 2 | 80 | 3 |
| other | Nausea | Gastrointestinal disorders | EOS POS Benralizumab 2 mg | 3 | 81 | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01238861/events